Ascletis Showcases ASC30, ASC37 and ASC39 Obesity Data at ADA 2026
HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...
COPENHAGEN, Denmark, May 27, 2026 Zealand Pharma announced that new clinical data from its obesity and metabolic disease pipeline...
NEW TAIPEI CITY, Taiwan, May 18, 2026 Caliway Biopharmaceuticals unveiled new preclinical findings at the European Congress on Obesity...
CAMBRIDGE, Massachusetts; ROTTERDAM, Netherlands; and SHANGHAI, China, May 18, 2026 Harbour BioMed announced promising preclinical data for LET003, its...
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
SEOUL, SOUTH KOREA | January 27, 2026 — Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced a...
